TrialPharmaceutical statistics2022

SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.

Yifei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.